Confidence in Concept 2012 - University College London

Lead Research Organisation: University College London

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding.  It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.

Publications

10 25 50

 
Description BBSRC PhD CASE studentship (in partnership with Syngenta) - Neil Millar
Amount £132,000 (GBP)
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start  
 
Description CRUK/Bayer Drug Discovery Award - Ashcroft
Amount £200,000 (GBP)
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Description Characterisation of innate immune DNA sensing and viral evasion strategies.
Amount £2,121,162 (GBP)
Funding ID 108183/Z/15/Z 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2015 
End 09/2020
 
Description Johnson and Johnson Innovation Fund - Neidle
Amount £99,476 (GBP)
Organisation Johnson & Johnson 
Sector Private
Country United States
Start  
 
Description MRC Quinquennial Programme Grant - Mark Marsh
Amount £24,000,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start  
 
Description PoC Fund - Caddick
Amount £29,876 (GBP)
Organisation UCL Business 
Sector Private
Country United Kingdom
Start  
 
Description Response mode grant - Caddick
Amount £600,000 (GBP)
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Academic/University
Country United Kingdom
Start  
 
Description Super follow-on Fund - Caddick
Amount £600,107 (GBP)
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start  
 
Description Translational Support Award (SBC) - Caddick
Amount £145,000 (GBP)
Organisation Albumedix Ltd 
Sector Private
Country United Kingdom
Start  
 
Description UCL Business PoC Award - Towers
Amount £54,996 (GBP)
Organisation UCL Business 
Sector Private
Country United Kingdom
Start 08/2013 
 
Description UCL Business Proof of Concept - Caddick
Amount £29,476 (GBP)
Organisation UCL Business 
Sector Private
Country United Kingdom
Start  
 
Description UCL Therapeutic Innovation Fund - Towers
Amount £59,387 (GBP)
Organisation University College London 
Sector Academic/University
Country United Kingdom
Start  
 
Description UCLH BRC SBC technology evaluation grant - Caddick
Amount £250,000 (GBP)
Organisation National Institute for Health Research 
Department NIHR Biomedical Research Centre
Sector Academic/University
Country United Kingdom
Start  
 
Description UCLH/UCL BRC grant - Towers - Development of broad specificity anti-viral drugs
Amount £199,555 (GBP)
Organisation National Institute for Health Research 
Department NIHR Biomedical Research Centre
Sector Academic/University
Country United Kingdom
Start 08/2016 
End 08/2019
 
Description UTF - Niedle
Amount £1,000,000 (GBP)
Organisation UCL Business 
Sector Private
Country United Kingdom
Start 01/2017 
End 12/2018
 
Description Wellcome Trust Senior Biomedical Research Fellowship - Towers
Amount £2,121,162 (GBP)
Organisation Wellcome Trust 
Department Wellcome Trust Senior Research Fellowship
Sector Private
Country United Kingdom
Start 10/2015 
End 09/2020
 
Description Ashcroft CiC collaboration with CRT 
Organisation Cancer Research Technology (CRT)
Country United Kingdom 
Sector Private 
PI Contribution Discovery of novel HIF pathway inhibitors for the treatment of cancer. UCL group provides project leadership, disease and HIF biology background knowledge and expertise along with medicinal chemistry and complex bioassay capabilities.
Collaborator Contribution CRT provided basic bioassay resource and some medicinal chemistry support.
Impact Active inhibitory compounds that form the basis of subsequent grant applications. Multi-disciplinary: Cell biology, medicinal chemistry, synthestic organic chemistry
Start Year 2015
 
Description Caddick CiC project collaboration with Novozymes 
Organisation Novozymes
Country Denmark 
Sector Public 
PI Contribution Thiologics is a UCL Business PLC (UCLB) wholly owned company spun-out of UCL Chemistry. The company aims to commercialise new bioconjugation technologies developed in the laboratories of Professor Stephen Caddick and Dr James Baker. ThioLogics is particularly focused on delivering technology that will enable the construction of homogeneous antibody-drug conjugate therapeutics (ADCs). Novozymes Biopharma has entered a new collaboration with UK-based biotechnology company ThioLogics. The collaboration brings together Novozymes' modified recombinant human albumin (rAlbumin) Veltis technology with ThioLogics' site-specific second generation maleimide conjugation platform. This allows Novozymes to offer the pharma industry serum stable albumin drug conjugates with enhanced pharmacokinetic and/or targeting capabilities.
Collaborator Contribution The collaboration brings together Novozymes' modified recombinant human albumin (rAlbumin) Veltis technology with ThioLogics' site-specific second generation maleimide conjugation platform. This allows Novozymes to offer the pharma industry serum stable albumin drug conjugates with enhanced pharmacokinetic and/or targeting capabilities.
Impact Too early to report on specific outcomes.
Start Year 2015
 
Description Marsh CiC project collaboration with GlaxoSmithKline (GSK) 
Organisation GlaxoSmithKline (GSK)
Country Global 
Sector Private 
PI Contribution Drug discovery for novel anti-vrial treatments
Collaborator Contribution Contribution of analogue compounds of active hits from screening.
Impact Further compounds have been avaialble for testing. Too early to know ultimalte benefit.
Start Year 2015
 
Title Antitumor HIF inhibitors 
Description The invention provides inhibitors of hypoxia-inducible factors (HIF), and their use in the prevention or inhibition of diseases characterized by abnormal HIF activity or levels, such as tumor progression, and the treatment of cancer. The invention encompasses pharmaceutical compns. with a mechanism of action for blocking elevated HIF activity in diseases, such as cancer. 
IP Reference WO2015079213 
Protection Patent application published
Year Protection Granted 2015
Licensed No
Impact To be determined
 
Title COMPOUNDS AND THEIR SYNTHESIS" (LIGHT ACTIVATED FLUORINATION) 
Description COMPOUNDS AND THEIR SYNTHESIS" (LIGHT ACTIVATED FLUORINATION) - hNET-Targeting Pro-Drugs for Treatment of Neuroblastoma 
IP Reference WO2014057291 
Protection Patent granted
Year Protection Granted 2012
Licensed No
Impact None as yet
 
Title Chemical modification of antibodies 
Description This is IP arising from the Caddick CiC award. Novel linkers for controlled conection of drug molecules to anibodies in the formation of Antibody-Drug-Conjugates (ADCs) 
IP Reference WO2013132268 
Protection Patent granted
Year Protection Granted 2013
Licensed Commercial In Confidence
Impact Early days, but has the potenrtial to transform the production of homogeneous ADCs
 
Title NAPHTHALENE DIIMIDE COMPOUNDS INTERACTING WITH G-QUADRUPLEX REGIONS IN DNA 
Description The invention relates to novel compounds which are naphthalene diimides. The compounds are used in therapy, particularly in cancer treatment. 
IP Reference WO2009068916 
Protection Patent granted
Year Protection Granted 2014
Licensed No
Impact To be determined
 
Title NON-IMMUNOSUPPRESSIVE CYCLOSPORIN DERIVATIVES AS ANTIVIRAL AGENTS 
Description This invention discloses n on-immunosuppressive cyclosporin derivatives as antiviral agents 
IP Reference WO2014132084 
Protection Patent application published
Year Protection Granted 2014
Licensed No
Impact To be determined
 
Title Preparation of bis(triazolyl)naphthalene derivatives as G-quadruplex stabilizing agents useful in treatment of proliferative disease 
Description The invention relates to bis(triazolyl)naphthalene derivatives as G-quadruplex stabilizing agents, and their prepn., useful in the treatment of proliferative disease including cancer, in particular renal cancer. 
IP Reference WO2012136997 
Protection Patent application published
Year Protection Granted 2012
Licensed No
Impact To be determined
 
Company Name Thiologics Limited 
Description Thiologics is a UCL Business PLC (UCLB) wholly owned company spun-out of UCL Chemistry. The company aims to commercialise new bioconjugation technologies developed in the laboratories of Professor Stephen Caddick and Dr James Baker. ThioLogics is particularly focused on delivering technology that will enable the construction of homogeneous antibody-drug conjugate therapeutics (ADCs). For further information, please contact Dr Chris Williams, Business Development Manager, c.williams@thiologics.com. 
Year Established 2011 
Impact Development of novel highly specific linker technologies used in the generation of Antibody-Drug-Conjugates
Website http://www.thiologics.com/